HUE039931T2 - Szfingozin-1-foszfát receptor agonisták, azok elkészítési eljárásai, és azokat aktív ágensként tartalmazó gyógyszerészeti készítmények - Google Patents
Szfingozin-1-foszfát receptor agonisták, azok elkészítési eljárásai, és azokat aktív ágensként tartalmazó gyógyszerészeti készítményekInfo
- Publication number
- HUE039931T2 HUE039931T2 HUE14753476A HUE14753476A HUE039931T2 HU E039931 T2 HUE039931 T2 HU E039931T2 HU E14753476 A HUE14753476 A HU E14753476A HU E14753476 A HUE14753476 A HU E14753476A HU E039931 T2 HUE039931 T2 HU E039931T2
- Authority
- HU
- Hungary
- Prior art keywords
- same
- sphingosine
- preparing
- methods
- pharmaceutical compositions
- Prior art date
Links
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title 1
- 239000013543 active substance Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130018293 | 2013-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE039931T2 true HUE039931T2 (hu) | 2019-02-28 |
Family
ID=51391525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE14753476A HUE039931T2 (hu) | 2013-02-20 | 2014-02-19 | Szfingozin-1-foszfát receptor agonisták, azok elkészítési eljárásai, és azokat aktív ágensként tartalmazó gyógyszerészeti készítmények |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9540362B2 (hu) |
| EP (1) | EP2958913B1 (hu) |
| JP (1) | JP6294359B2 (hu) |
| KR (1) | KR101939657B1 (hu) |
| CN (1) | CN105051037B (hu) |
| AU (1) | AU2014219575B2 (hu) |
| BR (1) | BR112015019794B1 (hu) |
| DK (1) | DK2958913T3 (hu) |
| ES (1) | ES2698359T3 (hu) |
| HU (1) | HUE039931T2 (hu) |
| MX (1) | MX370032B (hu) |
| PL (1) | PL2958913T3 (hu) |
| PT (1) | PT2958913T (hu) |
| RU (1) | RU2654483C2 (hu) |
| SI (1) | SI2958913T1 (hu) |
| TW (1) | TWI582073B (hu) |
| WO (1) | WO2014129796A1 (hu) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI692469B (zh) * | 2012-11-09 | 2020-05-01 | 南韓商Ｌｇ化學股份有限公司 | Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
| KR102644587B1 (ko) * | 2015-12-24 | 2024-03-07 | (주)아모레퍼시픽 | 유사 세라마이드 화합물 및 그 제조방법 |
| ES2975689T3 (es) * | 2016-01-29 | 2024-07-11 | Ono Pharmaceutical Co | Derivado de tetrahidronaftaleno |
| CN109661391B (zh) * | 2016-07-22 | 2022-04-19 | 南京明德新药研发有限公司 | S1p1激动剂及其应用 |
| EP3592739A1 (en) * | 2017-03-07 | 2020-01-15 | H. Hoffnabb-La Roche Ag | Oxadiazole transient receptor potential channel inhibitors |
| CN107382965A (zh) * | 2017-08-14 | 2017-11-24 | 河南科技大学第附属医院 | 具有抗肿瘤活性的新型s1p‑1受体激动剂药物分子的合成方法 |
| KR101891051B1 (ko) * | 2018-01-29 | 2018-08-31 | 주식회사 세종바이오메드 | 스핑고신-1-포스페이트 유사체 및 이의 합성 방법 |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| US11976052B2 (en) | 2019-01-11 | 2024-05-07 | Naegis Pharmaceuticals Inc. | Leukotriene synthesis inhibitors |
| CN110240537B (zh) * | 2019-05-22 | 2022-06-21 | 成都阿奇生物医药科技有限公司 | 一种茚氧乙酸类化合物及其制备方法和用途 |
| BR112022010761A2 (pt) * | 2019-12-03 | 2022-08-23 | Lg Chemical Ltd | Agonista do receptor de esfingosina-1-fosfato, método de preparação do mesmo e composição farmacêutica contendo o mesmo como ingrediente ativo |
| KR20210073998A (ko) | 2019-12-11 | 2021-06-21 | 주식회사 엘지화학 | 다발성 경화증 예방 또는 치료용 약제학적 조성물 |
| WO2022065940A1 (ko) * | 2020-09-28 | 2022-03-31 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제의 용도 |
| CA3192701A1 (en) * | 2020-09-28 | 2022-03-31 | Ki Chan Kim | Use of sphingosine-1-phosphate receptor agonist |
| EP4219443A4 (en) * | 2020-10-13 | 2024-04-17 | Lg Chem, Ltd. | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST |
| CN116323563A (zh) * | 2020-10-13 | 2023-06-23 | 株式会社Lg化学 | 制备用于合成鞘氨醇-1-磷酸酯受体激动剂的中间体的方法 |
| KR20220142383A (ko) * | 2021-04-14 | 2022-10-21 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제의 결정형 |
| WO2022220612A1 (ko) | 2021-04-14 | 2022-10-20 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법 |
| KR20220142379A (ko) * | 2021-04-14 | 2022-10-21 | 주식회사 엘지화학 | 습식과립법에 의한 스핑고신-1-인산 수용체 효능제를 포함하는 경구용 고형 제제의 제조 방법 |
| CN117177964A (zh) * | 2021-04-14 | 2023-12-05 | 株式会社Lg化学 | 制备鞘氨醇-1-磷酸酯受体激动剂的新方法 |
| KR20220142378A (ko) * | 2021-04-14 | 2022-10-21 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제를 포함하는 고형 제제의 제조 방법 |
| WO2022220598A1 (ko) * | 2021-04-14 | 2022-10-20 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제의 결정형 |
| WO2022220608A1 (ko) * | 2021-04-14 | 2022-10-20 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법 |
| WO2022220599A1 (ko) * | 2021-04-14 | 2022-10-20 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제의 결정형 |
| EP4321153A4 (en) * | 2021-04-14 | 2024-10-09 | Lg Chem, Ltd. | PHARMACEUTICAL COMPOSITION COMPRISING A SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST HAVING A CONTROLLED PARTICLE SIZE |
| EP4306516A4 (en) * | 2021-04-14 | 2024-09-11 | Lg Chem, Ltd. | NEW METHOD FOR THE PRODUCTION OF A SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST |
| WO2022220593A1 (ko) * | 2021-04-14 | 2022-10-20 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제를 포함하는 직접 타정용 약제학적 조성물 |
| JP2024515177A (ja) * | 2021-04-14 | 2024-04-05 | エルジー・ケム・リミテッド | スフィンゴシン－１－リン酸受容体アゴニストの薬学的に許容される塩及びその結晶形 |
| KR102658762B1 (ko) * | 2021-04-14 | 2024-04-19 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법 |
| US20240208930A1 (en) * | 2021-04-14 | 2024-06-27 | Lg Chem, Ltd. | Crystalline form of sphingosine-1-phosphate receptor agonist |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999011255A1 (fr) * | 1997-08-28 | 1999-03-11 | Ono Pharmaceutical Co., Ltd. | Regulateurs du recepteur active par les agents de proliferation des peroxysomes |
| CA2497901A1 (en) | 2002-09-06 | 2004-03-18 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
| WO2004063155A1 (en) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Fused heterocyclic derivatives as ppar modulators |
| US7425631B2 (en) | 2003-04-10 | 2008-09-16 | Amgen Inc. | Compounds and methods of use |
| JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| PT1826197E (pt) | 2004-12-13 | 2012-03-06 | Ono Pharmaceutical Co | Derivado de ácido aminocarboxílico e sua utilização medicinal |
| DE602006010991D1 (de) | 2005-01-26 | 2010-01-21 | Schering Corp | 3-(indazol-5-yl)-(1,2,4)triazinderivate und verwandte verbindungen als proteinkinaseinhibitoren zur behandlung von krebs |
| EP1996191A4 (en) | 2006-03-02 | 2010-05-19 | Glaxosmithkline Llc | THIAZOLONE AS A PI3 KINASE INHIBITOR |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| JP2009269819A (ja) | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
| AU2007323540A1 (en) * | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
| US20110207704A1 (en) | 2006-12-15 | 2011-08-25 | Abbott Laboratories | Novel Oxadiazole Compounds |
| AR064420A1 (es) | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| CA2692713A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Heterocyclic modulators of pkb |
| KR20100038119A (ko) | 2007-08-01 | 2010-04-12 | 화이자 인코포레이티드 | 피라졸 화합물 및 ｒａｆ 억제제로서 이의 용도 |
| GB0725101D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| SI2291080T1 (sl) | 2008-05-14 | 2015-11-30 | The Scripps Research Institute | Novi modulatorji sfingosinskih fosfatnih receptorjev |
| US8153103B2 (en) | 2008-07-01 | 2012-04-10 | Board Of Regents, The University Of Texas System | Conjugates of photo-activatable dyes |
| US9181182B2 (en) | 2008-10-17 | 2015-11-10 | Akaal Pharma Pty Ltd | S1P receptors modulators |
| BRPI0923178A2 (pt) | 2008-12-18 | 2016-02-16 | Merck Serono Sa | derivados heterocíclicos de oxadiazol fundidos úteis para o tratamento de esclerose múltipla |
| EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| US20100174539A1 (en) | 2009-01-06 | 2010-07-08 | Qualcomm Incorporated | Method and apparatus for vector quantization codebook search |
| KR20100092909A (ko) | 2009-02-13 | 2010-08-23 | 주식회사 엘지생명과학 | 잔틴 옥시다제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물 |
| EP2241558A1 (en) | 2009-04-03 | 2010-10-20 | Merck Serono SA | Oxadiazole derivatives |
| ES2821018T3 (es) | 2009-04-22 | 2021-04-23 | Resverlogix Corp | Nuevos agentes antiinflamatorios |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| AR077227A1 (es) | 2009-06-26 | 2011-08-10 | Glaxo Group Ltd | Compuesto de acido aril/ heteroaril- sustituido carboxilico, su uso para fabricar un medicamento util el tratamiento de afecciones o trastornos mediados por receptores s1p1, tales como esclerosis multiple y composicion farmaceutica que lo comprende |
| PH12012500938A1 (en) | 2009-11-13 | 2016-09-16 | Receptos Llc | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| WO2011060391A1 (en) * | 2009-11-13 | 2011-05-19 | Receptos, Inc. | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| CN102712618B (zh) * | 2009-11-24 | 2014-11-26 | 阿勒根公司 | 作为具有治疗效用的受体调节剂的新型化合物 |
| EP2390252A1 (en) * | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| CN103380112A (zh) * | 2010-11-24 | 2013-10-30 | 阿勒根公司 | 作为s1p受体调节剂的吲哚衍生物 |
| TWI692469B (zh) * | 2012-11-09 | 2020-05-01 | 南韓商Ｌｇ化學股份有限公司 | Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
-
2014
- 2014-02-19 BR BR112015019794-9A patent/BR112015019794B1/pt active IP Right Grant
- 2014-02-19 HU HUE14753476A patent/HUE039931T2/hu unknown
- 2014-02-19 MX MX2015009986A patent/MX370032B/es active IP Right Grant
- 2014-02-19 RU RU2015139594A patent/RU2654483C2/ru active
- 2014-02-19 ES ES14753476T patent/ES2698359T3/es active Active
- 2014-02-19 KR KR1020140019113A patent/KR101939657B1/ko active Active
- 2014-02-19 US US14/764,116 patent/US9540362B2/en active Active
- 2014-02-19 DK DK14753476.2T patent/DK2958913T3/en active
- 2014-02-19 AU AU2014219575A patent/AU2014219575B2/en active Active
- 2014-02-19 PL PL14753476T patent/PL2958913T3/pl unknown
- 2014-02-19 TW TW103105447A patent/TWI582073B/zh active
- 2014-02-19 PT PT14753476T patent/PT2958913T/pt unknown
- 2014-02-19 CN CN201480009397.9A patent/CN105051037B/zh active Active
- 2014-02-19 WO PCT/KR2014/001336 patent/WO2014129796A1/en active Application Filing
- 2014-02-19 EP EP14753476.2A patent/EP2958913B1/en active Active
- 2014-02-19 JP JP2015559180A patent/JP6294359B2/ja active Active
- 2014-02-19 SI SI201430907T patent/SI2958913T1/sl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201444794A (zh) | 2014-12-01 |
| TWI582073B (zh) | 2017-05-11 |
| CN105051037A (zh) | 2015-11-11 |
| US20150376173A1 (en) | 2015-12-31 |
| MX2015009986A (es) | 2015-10-05 |
| PT2958913T (pt) | 2018-12-03 |
| CN105051037B (zh) | 2018-05-18 |
| ES2698359T3 (es) | 2019-02-04 |
| JP2016513126A (ja) | 2016-05-12 |
| BR112015019794A2 (pt) | 2017-07-18 |
| BR112015019794B1 (pt) | 2022-09-13 |
| KR20140104376A (ko) | 2014-08-28 |
| EP2958913B1 (en) | 2018-10-03 |
| AU2014219575B2 (en) | 2017-07-06 |
| EP2958913A1 (en) | 2015-12-30 |
| RU2654483C2 (ru) | 2018-05-21 |
| BR112015019794A8 (pt) | 2018-08-14 |
| SI2958913T1 (sl) | 2018-12-31 |
| RU2015139594A (ru) | 2017-03-27 |
| MX370032B (es) | 2019-11-28 |
| PL2958913T3 (pl) | 2019-03-29 |
| WO2014129796A1 (en) | 2014-08-28 |
| US9540362B2 (en) | 2017-01-10 |
| DK2958913T3 (en) | 2018-11-05 |
| AU2014219575A1 (en) | 2015-08-20 |
| JP6294359B2 (ja) | 2018-03-14 |
| EP2958913A4 (en) | 2016-10-05 |
| KR101939657B1 (ko) | 2019-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2958913T3 (pl) | Agoniści receptora sfingozyno-1-fosforanowego, sposoby ich przygotowania i zawierające je jako środek aktywny farmaceutyczne kompozycje | |
| HRP20190164T1 (hr) | Paraziticidni oralni veterinarski sastavi koji obuhvaćaju djelatne tvari sa sustavnim djelovanjem, i načini njihove primjene | |
| EP2917180A4 (en) | GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE SUBSTANCE | |
| EP3065742A4 (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| HK1215567A1 (zh) | 五元併六元雜環化合物、其製備方法、藥物組合物和應用 | |
| IL240894A0 (en) | Combinations of decitabine derivatives and other active substances, kits and preparations containing them and their uses | |
| HK1221653A1 (zh) | 用於呼吸遞送三種或更多種活性劑的組合物、方法和系統 | |
| EP3012256A4 (en) | HETEROCYCLIC BENZIMIDAZOLE-2-PIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PROCESS FOR PREPARATION AND USE THEREOF | |
| EP3054933A4 (en) | Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same | |
| PL2961822T3 (pl) | Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie | |
| EP2941418A4 (en) | N1-CYCLIC AMIN-N5 SUBSTITUTED BIGUANIDE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH | |
| IL243223B (en) | History of imidazole, their preparation and pharmaceutical preparations containing them | |
| MX367773B (es) | Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos. | |
| UA88242U (ru) | Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства гипогликемического действия | |
| HUE044798T2 (hu) | Agomelatin és p-toluol-szulfonsav kokristályai, eljárás elõállításukra, és ezeket tartalmazó gyógyszerészeti készítmények |